Antiplatelet drug update that walks readers through the developer's background, summarized clinical findings, and plans for global commercialization.
Key Takeaways
- China's NMPA formally accepted the drug's NDA for regulatory review
- Phase III trials showed a trend toward lower MACCE risk versus clopidogrel
- Everest Medicines secured exclusive Asia-Pacific licensing rights for the product